Lidoflazine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
Physical properties
Physical properties
Solubility at room temperature
Extracted from [2]
| Solvent | 0.01
N |
0.1
N | ||
| % | pH | % | pH | |
| Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
| Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
| Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
| Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
| Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
References
References
- ↑ Schaper, W.K.A.; Xhonneux, R.; Jageneau, A.H.M.; Janssen, P.A.J. (1966). “The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator”. Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369. Retrieved 2009-06-20.
- ↑ http://jpet.aspetjournals.org/cgi/content/abstract/152/2/265
- Schaper WK, Xhonneux R, Jageneau AH., Stimulation of the coronary collateral circulation by lidoflazine (R 7904), Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 Nov 4;252(1):1-8.
- Schaper WK, Xhoneux R, Jageneau AH, Janssen PA., The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator, J Pharmacol Exp Ther. 1966 May;152(2):265-74.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH